High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma

Table 1 Clinical characteristics of MYCN amplified cases

Case	Sex	Age at Diagnosis	Diagnosis	Location at Diagnosis	LMD at Diagnosis	Spine involvement	Recurrences	Location of recurrence	Followup	Disease Status	Prior Oncological Hx
1	M	52	A-EPN (grade III)	T, B	Yes	ID, EM	0	NA	2	Alive	Basal Cell Ca
2	F	24	A-EPN (grade III)	C, T, L	Yes	ID, EM	0	NA	14	Alive	None
3	F	30	A-EPN (grade III)	T	No	ID, IM	3	T	17	Alive	None
4^a	M	36	A-EPN (grade III)	T	No	unknown	4	C, LS	55	Alive	None
5	F	37	A-EPN (grade III)	T	No	ID, EM	3	T, B	62	Alive	None
6	F	35	A-EPN (grade III)	C, T	No	ID, EM	2	T	63	Alive	None
7	M	52	A-EPN (grade III)	C, T, L	Yes	ID, EM	1	C, T, L	80	Deceased	None
8	M	29	A-EPN (grade III)	C	Yes	ID, EM	12	C, B	85	Deceased	None

^a Case from CERN archive
Abbreviations: LMD leptomeningeal disease, T thoracic, B brain, C cervical, L lumbar, LS lumbosacral, ID Intradural, EM extramedullary, IM Intramedullary

ISSN: 2051-5960